Vitex (Chasteberry) for PCOS: Weak Evidence, Real Interactions

Does Vitex (Chasteberry) Actually Work for PCOS?

A 2013 systematic review found 12 randomised, controlled trials of vitex extracts worth including, and eight of them tested premenstrual syndrome, not PCOS. Of the remainder, two tested premenstrual dysphoric disorder and two tested latent hyperprolactinaemia with a luteal phase defect — a hormonal pattern that overlaps with PCOS in one respect (both can involve irregular ovulation) but is a distinct diagnosis, not PCOS itself. None of the 12 trials in that review enrolled women specifically for PCOS.

That changed only in 2026, with the first small trial built around a PCOS diagnosis. One trial does not settle the question — see below for exactly what it did and did not measure.

What Vitex Is, and Why It Would Touch PCOS at All

Vitex agnus-castus — also sold as chasteberry or agnus castus, the same plant under three names — contains a class of diterpene compounds called clerodadienols that bind directly to the dopamine D2 receptor. Dopamine’s normal job at that receptor is to suppress the release of prolactin from the pituitary gland, and laboratory and animal work shows these compounds do almost the same thing dopamine itself does. That is the entire mechanism: vitex acts like a mild dopamine agonist, and dopamine agonism lowers prolactin.

This matters for PCOS only indirectly. Elevated prolactin can disrupt ovulation and shorten the luteal phase — the second half of the cycle, after ovulation — independent of PCOS. Some people with PCOS also happen to run a mildly elevated prolactin. Vitex’s plausible target is that overlap, not the androgen or insulin pathways that drive most of PCOS itself.

The One PCOS-Specific Trial, in Full

Sixty women with PCOS were randomised to standardised vitex extract (5.8 mg daily) or placebo for 12 weeks in a 2026 single-centre trial — the first RCT built around a PCOS diagnosis rather than PMS or hyperprolactinaemia. Its primary outcome was oxidative stress markers, not androgens or ovulation. On that primary measure, vitex improved total antioxidant capacity and reduced markers of oxidative stress relative to placebo.

Secondary outcomes moved too: fasting blood sugar and HOMA-IR (insulin resistance) fell modestly, LDL and an inflammation marker fell, hirsutism score improved, and menstrual frequency increased. These are real, statistically reported findings — and also a single trial, from one centre, that has not been replicated, with androgens and ovulation as secondary rather than primary endpoints. One trial with encouraging secondary findings is a reason to watch this space, not a reason to treat vitex as established for PCOS.

Vitex is also sold as an unregulated supplement, and the trial used a product standardised to a specific marker compound — 0.42 to 0.82 mg of aucubin per 5.8 mg dose. Most over-the-counter vitex products do not disclose whether they match that standardisation, so a bottle bought off a shelf is not guaranteed to deliver what the trial tested, even at the same milligram count on the label.

The Interactions That Matter

Because vitex’s mechanism is dopaminergic, it can plausibly interact with two categories of medication in opposite directions:

• Dopamine agonists (bromocriptine, cabergoline — used to treat true hyperprolactinaemia or prolactinomas): combining these with vitex could compound the prolactin-lowering effect beyond what either alone would do.
• Dopamine antagonists (many antipsychotics, and some anti-nausea medications): vitex’s dopamine-agonist activity could theoretically work against these drugs’ intended effect on dopamine pathways.

Neither interaction has been tested in a clinical trial — this is pharmacological reasoning from vitex’s known mechanism, not a documented interaction study. A 2023 review that looked specifically for evidence on vitex and prolactin, including in PCOS, reached the same conclusion: no large randomised trials exist to confirm how it behaves in that setting, which is exactly why the interaction risk above should not be treated as settled either way.

Vitex is also not appropriate to combine with hormonal PCOS treatment — combined oral contraceptives, ovulation-induction medication, or any prescribed hormone therapy — without telling the prescriber. The two are not known to be dangerous together, but nobody has studied the combination, and a supplement that measurably shifts prolactin and luteal-phase hormones is not one to stack silently onto a treatment plan your clinician doesn’t know about.

You may also see PCOS written as polyendocrine metabolic ovarian syndrome (PMOS), after a 2026 global consensus of more than 50 organisations renamed it. Nothing about the vitex evidence above changes under either name — this article uses PCOS because that is still what people search.

Who This Won’t Help

Weighed against the rest of this site’s supplements and medications section, vitex is one of the weaker PCOS-specific options on offer. It will not help you if:

• Your prolactin isn’t elevated. Vitex’s one plausible mechanism has no target to act on. There is no trial evidence it changes testosterone, insulin resistance, or ovarian follicle count directly.
• You’re already on a dopamine agonist, a dopamine antagonist, or hormonal treatment without your prescriber knowing — see the interactions section above.
• As a fertility treatment on its own. The luteal-phase normalisation seen in the Milewicz trial was in a non-PCOS population; vitex has not been tested against ovulation rates or live births in PCOS. For tracking ovulation on an irregular cycle, pcos ovulation tracking covers what actually works.
• As a fast-acting option. The one trial that ran long enough to detect change did so over 12 weeks — nothing shorter has been tested.

Spearmint tea and DIM are the other two botanicals people ask about alongside vitex, and the honest evidence picture is different for each: spearmint tea has two small hormone trials that moved testosterone but not the hirsutism score, while DIM has no PCOS trials at all. For where all three rank against options with stronger evidence, like inositol and vitamin D, see the evidence-ranked supplements guide.

Common questions